Subscribe To

Price Alert Latest News Economic Calendar News

BAX / Baxter International Inc. (BAX) CEO José Almeida on Q2 2022 Results - Earnings Call Transcript

Baxter International Inc. (NYSE:BAX ) Q2 2022 Results Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Clare Trachtman - Vice President, Investor Relations José Almeida - Chairman, President and Chief Executive Officer James Saccaro - Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus – J.P. Morgan Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Travis Steed - Bank of America Securities Joanne Wuensch - Citigroup Larry Biegelsen - Wells Fargo Joshua Jennings - Cowen and Company Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2022 Earnings Conference Call. Read More

Demo Live Account See Partner Details

Content Topics

Baxter

International

Inc

BAX

Jos

Almeida

2022

Results

Earnings

Transcript

Stock

Posted: Jul 28 2022, 11:06

Author Name: Seeking Alpha

BAX News

By Zacks Investment Research
November 3, 2023

Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to com

By Reuters
November 2, 2023

Baxter International beats Q3 profit estimates on strong demand for medical devices

Baxter International on Thursday beat Wall Street expectations for third-quarter revenue and profit, as a recovery in surgical procedure volumes after

By Zacks Investment Research
October 30, 2023

BAX vs. SYK: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or Stryker (SYK). But which of

By Zacks Investment Research
October 30, 2023

Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?

Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products mig

By Zacks Investment Research
October 18, 2023

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatm

By CNBC Television
October 11, 2023

What other industries could weight loss drugs disrupt?

Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of w

By The Motley Fool
October 11, 2023

Why Investors Punished Baxter International Stock Today

A drug made by a rival tested well in a clinical trial for kidney disease. That treatment is currently a very hot product, but for different indicatio

By Zacks Investment Research
October 11, 2023

The 3 Widest Competitive Moats on Wall Street

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.